Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1516 of 5804
-
Sickle cell drug inclacumab safety checked in long-term study
Disease control TerminatedThis study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Fiber fix? new study tests prebiotics for diabetes control
Disease control Recruiting nowEvidence suggests that prebiotic fibre can correct dysbiosis, reduce intestinal permeability and improve glycemic control. The investigators hypothesize that microbial changes induced by prebiotics contribute to gut and endocrine adaptations that reduce glucose fluctuations, incl…
Phase: NA • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Second chance: drug combo retested for leukemia relapse
Disease control Recruiting nowChronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combinati…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Phase: PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for early liver cancer: radioembolization under the microscope
Disease control OngoingThe aim of the current study is to analyze treatment outcomes (best target lesion response, overall survival, time to target lesion progression, time to overall progression, and treatment-related adverse event) using prospectively collected clinical and imaging data in patients w…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Dads take the lead: new program aims to stop child abuse before it starts
Prevention OngoingThe goal of this observational study is to assess the American Psychological Association's ACT Raising Safe Kids program with male caregivers. The main question\[s\] it aims to answer are: • Will male caregivers in the ACT Raising Safe Kids program report lower child maltreatment…
Sponsor: Georgia State University • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Boosting the immune system after transplant: could 'Killer' cells prevent relapse?
Disease control CompletedThe goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant. The main questions it aims to answer are: * What adverse events occur within 2 years following CIK in…
Phase: NA • Sponsor: LucasBio • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can a simple inhaler stop lung bleeding?
Symptom relief CompletedThe study aims is to verify the hypothetize that inhaled Tranexamic Acid (TXA) or Terlipressin (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. This randomized double-blind multicenter triple arm trial compares the administration…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Blood filtering therapy shows promise for MS in early trial
Disease control CompletedPHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis (RRMS). The primary objective is the safety profile ass…
Phase: PHASE1, PHASE2 • Sponsor: Abu Dhabi Stem Cells Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
One-year survival and recovery in elderly COVID-19 patients under scrutiny
Knowledge-focused CompletedSARS-COV-2 infection can progress to acute respiratory distress syndrome and require hospitalization in the ICU in 5-20% of affected patients. Age is a major risk factor for developing a severe form and for death. ARDS related to SARS-COV-2 has specific features, including the ne…
Sponsor: Centre Hospitalier le Mans • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Thousands to test new migraine meds in largest Real-Life study
Disease control Recruiting nowApproved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of migraine due to their selectivity and specificity. To da…
Sponsor: IRCCS San Raffaele Roma • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill targets Hard-to-Treat cancers after other drugs fail
Disease control OngoingThe main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly long…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC
-
New hope for young hemophilia patients: jivi safety trial shows promise for fewer injections
Disease control CompletedResearchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood. People with hemophilia A may bleed for a long time from minor wounds, have …
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy for chronic migraine: atogepant plus botox under study
Disease control CompletedMigraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data sought on ibalizumab for Tough-to-Treat HIV
Disease control OngoingThe virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogene…
Sponsor: Theratechnologies • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy targets Hard-to-Treat bile duct cancer
Disease control OngoingThe purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Phase: PHASE1, PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a brain injury coach keep ex-inmates from returning to prison?
Disease control OngoingThe purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a cholesterol drug boost immunotherapy in lung cancer?
Disease control TerminatedThis is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer). Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs…
Phase: PHASE2 • Sponsor: Eziafa Oduah, MD, PhD, MPH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immune cell boost could keep leukemia at bay after transplant
Disease control OngoingThe purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with A…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a 3-Day course ease chronic fatigue? new trial aims to find out
Symptom relief Recruiting nowChronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal proble…
Phase: NA • Sponsor: Norwegian University of Science and Technology • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC